| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 106.1 | 107.8 |
| Gross profit | 84.4 | 75.5 |
| Profit before tax | -97.6 | 97.8 |
| Net income | -73.9 | 89.9 |
| EPS (diluted, $ a share) | $-1.03 | $1.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -1.6% |
|---|---|
| Gross margin | 79.5% |
| Operating margin | 39.7% |
10-Q filed with the SEC, NASDAQ: INVA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Innoviva, Inc.: key numbers
- Share price
- $18.49Close, Nov 16
- Market cap
- $1.31B
- Shares outstanding
- 71.08MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Innoviva, Inc.
All →Innoviva Financial Results
Innoviva reported third quarter 2026 financial results, featuring total revenue of $106.1 million and a 45% year-over-year increase in U.S. net product sales to $43.3 million. Despite strong operational income of $42.2 million, the company recorded a net loss of $73.9 million due to a $139.5 million unfavorable change in the fair value of its equity investments, primarily Armata Pharmaceuticals.
- Counterparty
- Glaxo Group Limited
- Term
- Q3 2026
“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.”
Pavel Raifeld, Chief Executive Officer of Innoviva
“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation.”
Pavel Raifeld, Chief Executive Officer of Innoviva